Cardiovascular effects of GLP-1 RAs have been of great interest since the burden from cardiovascular diseases (CVD) has been unbearably increasing in a diabetic population worldwide, despite strict glycemic control and advanced therapeutic techniques to treat CVD
The absence of such behavioral counseling can impede understanding and expectations around medication use and side effects, efficient clinical follow-up, overall efficacy, and long-term weight maintenance
The doses approved by regulatory bodies have been determined through rigorous phase III clinical trials involving thousands of participants, with careful assessment of both efficacy and safety profiles
468 Specifically, these agents can attenuate the excitability of carotid body cells and diminish sympathetic activation, ultimately leading to a reduction in sympathetic responses
Concurrent illness or major life stress occurring alongside GLP-1 therapy
It has been shown that glucagon can bind to GLP-1R, with a 1001000-fold decreased affinity than GLP-1, promoting insulin release due to its homology with GLP-1
